Long-Term @entity5015 Infusion for Newborns with Critical XXXX .

@entity1 @entity1084 @entity5015 @entity299 @entity386
UNASSIGNED: @entity5015 is crucial for keeping the patent ductus arteriosus in critical @entity299 for the survival and palliation of particularly prematurely born babies until a cardiosurgical intervention is available. In this study, the side effects of @entity5015 in newborns with critical @entity299 and clinical outcomes were evaluated. Thirty-five newborns diagnosed with critical @entity299 were treated with @entity5015 between January 2012 and September 2014 at our hospital. @entity1 charts were examined for @entity5015 side effects (metabolic, @entity1084 , @entity386 ), clinical status, and prognosis. Acquired data were analyzed in the SPSS 20.0 program. @entity1 with birth weight under 2500  g needed more days of @entity5015 infusion than ones with birthweight over 2500  g (P  =  0.016). The ratio of @entity1 with birth weight under 2500  g who received @entity5015 longer than 7  days was higher than the @entity1 with birth weight over 2500  g (P  =  0.02). Eighteen side effects were encountered in 11 of 35 @entity1 (31  %). Of these side effects, 1 @entity1 had 4, 4 @entity1 had 2, and 6 @entity1 had only 1 side effect. Discontinuation of the therapy was never needed. @entity5015 is an accepted therapy modality for survival and outcome in critical @entity299 in particularly low-birth-weight babies until a surgical intervention is available. Side effects are not less encountered but are almost always manageable, and discontinuation is not needed.
